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Objective: Osteoarthritis (OA) is a complex and painful disease of the whole joint. At present there are no
satisfying agents for treating OA. To promote OA research and improved treatment, this review sum-
marizes current preclinical evidence on the development of OA.
Methods: Preclinical OA research was searched and key ﬁndings are summarized and commented.
Results: Mechanisms of OA-associated pain have been studied in rodent knee OA models produced by
intra-knee injection of the chondrocyte glycolytic inhibitor mono-iodoacetate (MIA), surgery, or spon-
taneous development in some species. These models are clinically relevant in terms of histological
damage and functional changes, and are used to study mechanisms underlying mechanical, thermal,
ambulatory, body weight supporting-evoked, and ongoing OA pain. Recent peripheral, spinal, and
supraspinal biochemical and electrophysiological studies in these models suggest that peripheral pro-
inﬂammatory mediators and neuropeptides sensitize knee nociceptors. Spinal cytokines and neuro-
peptides promote OA pain, and peripheral and spinal cannabinoids inhibit OA pain respectively through
cannabinoid-1 (CB1) and CB1/CB2 receptors. TRPV1 and metalloproteinases contribute and supraspinal
descending facilitation of 5-hydroxytryptamine (5-HT)/5-HT 3 receptors may also contribute to OA pain.
Conditioned place preference tests demonstrate that OA pain induces aversive behaviors, suggesting the
involvement of brain. During OA, brain functional connectivity is enhanced, but at present it is unclear
how this change is related to OA pain.
Conclusion: Animal studies demonstrate that peripheral and central sensitization contributes to OA pain,
involving inﬂammatory cytokines, neuropeptides, and a variety of chemical mediators. Interestingly,
brainstem descending facilitation of 5-HT/5-HT3 receptors plays a role OA pain.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA), is a complex disease of the whole joint, is
characterized by structural degradation of the articular cartilage,
peri-articular bone, synovial joint lining, and adjacent supporting
connective tissue elements. It manifests as joint pain and loss of
joint function. There are currently no satisfying treatments to this
disease. The current standard of care is to manage and alleviate
symptoms1, but despite treatment with conventional analgesic
drugs most individuals with OA continue to experience pain2. A
recent study demonstrated that subjects with chronic back pain
and complex regional pain syndrome had signiﬁcantly less bilateral
hippocampal volume compared to controls, while those with OA
did not3. This suggests that OA-induced pain might be related to: R. Dubner, Department of
tal School, 650 W. Baltimore
1, USA. Tel: 1-410-706-0860;
(R.-X. Zhang), kren@
. Dubner).
s Research Society International. Punique mechanisms and this has attracted researchers’ attention in
recent years. Since themost common joints affected by OA are large
weight-bearing joints such as hip and knee4, intra-knee injection of
the chondrocyte glycolytic inhibitor mono-iodoacetate (MIA)-,
surgically induced, and spontaneous knee OA models have been
used to investigate mechanisms of OA-induced pain5e8.
In the MIA model, histological examination shows chondrocyte
degeneration/necrosis at days 1e7 post-MIA, increased osteoclasts
and osteoblasts in subchondral bone by day 7, focal fragmentation
and collapse of bony trabeculae with ﬁbrosis by day 28, and large
areas of bone remodeling by day 569,10. In vivomicroCT-arthrography
clearly detects cartilage degeneration in the injected knee11.
Tramadol, celecoxib, and diclofenac improve movement-
induced pain behavior evaluated with compressive hind limb grip
force in the MIA model12, and subcutaneous morphine and gaba-
pentin signiﬁcantly decrease the mechanical and thermal sensi-
tivity and ambulation-evoked pain13. MIA-induced articular
cartilage loss, progressive subchondral bone lesions, and the efﬁ-
cacy of clinical analgesics in inhibiting MIA-induced pain indicate
that this model is clinically relevant and will continue to be usefulublished by Elsevier Ltd. All rights reserved.
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understanding of the mechanisms of chronic OA pain.
Surgery-induced medial meniscal tear (MMT), partial medial
meniscectomy (PMM), destabilization of the medial meniscus
(DMM), and anterior cruciate ligament transection (ACLT) have
been used to induce knee OA14,15. The MMT results in a progressive
cartilage lesion16. The MMT plus ACLT-induced OA model presents
bone and cartilage remodeling, inﬁltration of immune cells into
joint tissues, and pain17. The ACLT þ PMM model showed no hind-
limb difference in gait analysis or mechanical allodynia over a
period of a month18, making it analogous to patients who show
radiological changes but no pain. PMM in female C57BL/6 mice
produces progressive degenerative joint damage and OA-related
pain19. The DMM-induced OA model displays a time-dependent
cartilage lesion between 2 and 12 weeks, including cartilage sur-
face ﬁbrillations, loss of superﬁcial cartilage and ulceration of
subchondral bone, and produces pain assessed 12 weeks after
surgery7. In that model, opioid receptor antagonists led to pain
onset 4 weeks earlier than in vehicle-treated animals, and opioid
receptors increased in the peripheral nerves that innervate the joint
in naloxone-responsive mice7, suggesting that endogenous opioids
might inhibit early-stage OA pain.
Guinea pigs, particularly the Dunkin-Hartley strain, STR/1N,
STR/ort, and C57 black mice, and several transgenic and genetically
altered strains of mice develop characteristics of arthritic joints, but
rats rarely develop them spontaneously (for a review, see D’Souza
et al., 2011). In Duncan-Hartley guinea pigs, age-dependent carti-
lage degeneration can be assessed by T(1r) magnetic resonance
imaging (MRI) from 3 to 9 months20.
All three model types have been used to investigate the mech-
anisms of OA pain, which has been assessed with various methods,
including mechanical, thermal, ambulatory, and body weight
supporting-evoked methods (for a review, see D’Souza et al., 2011).
MIA has been reported to be differentially potent: weight-
bearing von Frey ﬁlaments> runningwheel21. Von Frey ﬁlaments
are a set of calibrated ﬁlaments used to perpendicularly stimulate
skin. Recently, the MIA model has also been used to study ongoing
pain assessed with conditioned place preference 22,23. Additionally,
it has been reported that biglycan (BGN) and ﬁbromodulin (FMOD)Fig. 1. Diagram illustrating mechanisms of OA-induced pain. Bioactive chemicals are involve
IL-17, interleukin-17; IL-1a/b, interleukin alpha/beta.play roles in regulating chondrogenesis and extracellular matrix
turnover24 and that doubly deﬁcient BGN/FMOD mice develop
premature temporomandibular joint OA25. Peripheral, spinal, and
supraspinal l mechanisms (Fig. 1) have recently been discovered
using these rodent models.
Peripheral mechanisms
Cytokines
Synovitis is highly correlated to OA patients’ pain26,27 and plays
an important role in such pain2,28. An intra-articular MIA injection
signiﬁcantly increased tumor necrosis factor-a (TNF-a) and
interleukin-6 (IL-6) in the knee synovium and capsule between days
1 and 28 post-MIA; the levels of TNF-a and IL-6 peaked at day 4. The
injection also induced mechanical allodynia of the ipsilateral hind
paw, which was signiﬁcantly mitigated by local application of
nonsteroidal anti-inﬂammatory drugs (NSAIDs)29,30. A TNF-a injec-
tion into the normal knee joint caused signiﬁcant and persistent
sensitization of nociceptive sensory ﬁbers tomechanical stimuli that
was abolished by co-administration of etanercept, a TNF-a inhibitor;
and TNF-a induced excitation of isolated dorsal root ganglion (DRG)
neurons with C-ﬁber axons31 and increased mechanosensitivity and
peripheral receptive ﬁelds of DRG neurons32.
An electrophysiological study demonstrated increased sponta-
neous activity in C-mechanosensitive ﬁbers and increased me-
chanical sensitivity in A-mechanosensitive ﬁbers of the knee in
MIA-treated rats33. Furthermore, knee primary afferents, thinly
myelinated type III and unmyelinated type IV ﬁbers, showed sig-
niﬁcant mechanosensitivity in response to normal and noxious
joint rotation as compared to saline controls in an MIA model34,35.
This was reduced by local NSAID application35. Collectively, these
studies indicate that increased TNF-a sensitizes primary afferents
to facilitate joint pain and that NSAIDs can alleviate OA-induced
pain by inhibiting TNF-a expression.
IL-6 increased intracellular calcium in cultured DRG neurons in
calcium-imaging studies. Additionally, glycoprotein 130, to which
the IL-6/IL-6R complex binds, was found in almost all DRG neurons
cultured from adult rats. This suggests functional IL-6 receptors ind in OA-induced pain at peripheral, spinal and supraspinal levels. IL-13, interleukin-13;
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jection into the normal knee joint increased C-ﬁber response to
noxious outward rotation, and co-administration of IL-6 and its
soluble receptor signiﬁcantly increased response to innocuous
outward rotation37. These studies indicate that IL-6 sensitizes pri-
mary nociceptors in the knee.
IL-1b expression was higher between days 120 and 180 in
cartilage, menisci, synovia, and subchondral bone in OA-prone
Hartley than in OA-resistant Strain 13 guinea pigs. This parallels
the fact that OA develops faster in Hartley than in Strain 13
animals38. It has been shown that an IL-1b application increases
DRG neuron mechanosensitivity32. IL-1b treatment for 5e6 days
increased the excitability of medium- and small-diameter isolectin
B(4) (IB(4))-positive DRG neurons through its receptor, IL-1RI39.
Further, in an electrophysiological study, the mechanical threshold
required to initiate afferent ﬁring was signiﬁcantly lower in aged
(9e12 months) guinea pigs than in young (12e14 weeks) ones40.
Thus, IL-1b might sensitize primary nociceptors in the knee.
Other pro-inﬂammatory cytokines such as IL-7, IL-17, and IL-18
have also been implicated in synovitis, subchondral bone damage,
and cartilage homeostasis alteration in spontaneous or surgically
induced OA animal models and in transgenic mice primed to
develop OA41. Of these, IL-17 plays a critical role in nociception
during antigen-induced arthritis42. Local IL-17 is signiﬁcantly higher
in a mouse model of arthritis, and treatment with the antibody
against IL-17 inhibits hypernociception. Intra-articular IL-17 also
induced nociception and upregulation of TNF-a, IL-1b, keratinocyte-
derived chemokine (KC/CXCL1), prostaglandin E2 (PGE2), matrix
metalloproteinases-9 (MMP-9) activity, and cyclooxygenase-2
(COX-2) in synovial membranes42. Consistent with these data,
treatment with the non-speciﬁc MMP inhibitor doxycycline, the
COX inhibitor indomethacin, the anti-TNF antibody inﬂiximab, or
an IL-1 receptor antagonist inhibited IL-17-induced hyper-
nociception42. Intra-articular IL-17 also elicited slow-developing,
long-lasting sensitization of nociceptive C ﬁbers of the joint to
mechanical stimuli43. IL-17A receptors were found in most rat DRG
neurons, and IL-17 enhanced excitability of cultured DRG neurons43.
Therefore, although the role of IL-17 in OA pathophysiology is not
entirely established, IL-17 appears to play a role in OA-induced pain.
In accordance with studies in animals, synovial tissue from pa-
tients with all grades of OA show inﬂammatory cell inﬁltration and
cytokine production44. Human OA synovial cell cultures demon-
strated that macrophages produce TNF-a and IL-145. When DRG
from adult rats were co-cultured with normal or knee OA synovial
the mRNA levels of substance P (SP), neurokinin/tachykinin re-
ceptors (NK1, NK2), neuropeptide Y receptors (NPYR1, NPYR2), the
calcium channel a2d1, and inﬂammation mediators such as
COX2, IL-6, and interferon b2 were clearly elevated in these DRG
compared to control synovia46. This suggests that human OA
synovium-produced cytokines sensitize primary sensory neurons
and that blocking peripheral cytokine activity might alleviate OA
pain. Indeed, clinical researchers have been investigating a novel IL-
1 inhibitor for OA treatment47. It was showed that human mono-
clonal antibody to IL-1RI, AMG 108, showed greater improvements
in pain than placebo. Although some studies showed no statistically
signiﬁcant difference of Western Ontario and McMaster Univer-
sities Osteoarthritis Index (WOMAC) score between IL-1 receptor
antagonist, orthokine, and placebo groups, some data demon-
strated that orthokine considerably improved clinical signs and
symptoms of knee OA patients47.
Neuropeptides
Inﬂamed synovia also produce vasoactive intestinal peptide
(VIP) to cause pain48. Local application of VIP to normal kneessigniﬁcantly increased afferent ﬁring in response to normal rota-
tion and hyper-rotation that was blocked by pre-administration of
the VIP receptor antagonist VIP (6e28), and VIP (6e28) signiﬁcantly
reduced afferent ﬁring in MIA-injected rats49. Behaviorally, VIP
induced hind limb incapacity and mechanical allodynia in the hind
paw, while VIP (6e28) diminished these symptoms50. This suggests
that VIP sensitizes primary knee joint nociceptors during knee OA.
Cannabinoids
Studies show that activation of peripheral cannabinoid-1 (CB1)
receptors with local application of the CB1 receptor agonist
arachidonyl-2-chloroethylamide (ACEA) reduces mechanosensi-
tivity of afferent nerve ﬁbers in control and OA knee joints. The CB1
receptor antagonist AM251 signiﬁcantly increased mechanosensi-
tivity in the OA joint but not in controls. This indicates that MIA-
induced OA activates endogenous CB1 receptors in the knee that
in turn decrease the excitability of afferent ﬁbers. Further, a tran-
sient receptor potential vanilloid 1 (TRPV1) ion channel antagonist
signiﬁcantly reduced the efﬁcacy of ACEA, which suggests that
TRPV1 is involved in CB1 receptor-mediated anti-nociception34.
A local injection of the endocannabinoid hydrolysis inhibitor
URB597, which blocks anandamide catabolism, signiﬁcantly
inhibited afferent nerve activity in MIA-treated joints but had no
effect on saline-treated joints. Inhibition was prevented by CB1 but
not CB2 antagonist pretreatment. Behaviorally, URB597 produced
CB1- but not CB2-dependent analgesia. Similarly, URB597 inhibited
afferent nerve activity in the aged guinea pig knee OA animalmodel
but not in the young guinea pig40. Those data conﬁrm that pe-
ripheral CB1 activation can relieve OA-induced pain.
CB2 and TRPV1 receptor co-localization in synoviocytes of
sham- and MIA-treated rats suggest that CB2 receptors play a role
in pain51. Local application of the CB2 receptor agonist GW405833
signiﬁcantly reduced joint afferent ﬁring rate in control knees but
potentiated ﬁring in OA knee joint mechanoreceptors. This illus-
trates the paradoxical effects of CB2 in healthy and pathological
joints. GW405833 also increases calcitonin gene-related peptide
(CGRP) release via a TRPV1 channel-dependent mechanism to
facilitate pain51. These studies show that CB1 and CB2 have
different effects on OA-associated pain.
MMPs
MMPs are zinc-dependent endopeptidases that play an impor-
tant role in OA pathogenesis52. Recent studies demonstrate the
analgesic efﬁcacy of MMP inhibitors in OA pain. A non-selective and
equipotentMMPe 2, 8, 9,12, and13 inhibitor reduced osteochondral
vascularity, chondropathy, and weight-bearing asymmetry in a rat
knee OA model induced by transecting the medial collateral liga-
ment and cutting the full thickness of the meniscus of the knee53.
A speciﬁc MMP-13 inhibitor not only signiﬁcantly reduced MIA-
induced cartilage damage but also improved weight bearing in
an MIA-injected hind limb54. Additionally, the protease inhibitor
MG132 reduces pain and reverses cartilage MMP-3 upregulation55.
These studies indicate that protease inhibitors such as selectiveMMP
inhibitors produce both chondroprotection and analgesia during OA.
Other bioactive agents
In the MIA-induced knee OA model, ABC29464056, a selective
inhibitor of sphingosine kinase-2; AS189280257,58, which rarely
penetrates the central nervous tissue and is a selective Rho kinase
inhibitor; and MEN1613259, a kinin B(2) receptor antagonist,
signiﬁcantly improved weight bearing of the injected limb and
alleviated cartilage degradation. Systemic co-administration of the
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analgesic potency of the nicotinic acetylcholine receptor (nAChR)
a4b2 agonist ABT-594 5-fold60. These studies indicate that sphin-
gosine kinase-2, Rho kinase, kinin B(2) receptors, and nAChR are
involved in OA pain. Rebamipide, a free radical scavenger61,
signiﬁcantly inhibited MIA-induced pain and cartilage degenera-
tion by decreasing MMP-13, IL-1b, hypoxia-inducible factor-2alpha
(HIF-2a), inducible NO synthase (iNOS), and nitrotyrosine expres-
sion in OA cartilage and by increasing tissue inhibitor expression of
MMP-1 and MMP-362. This suggests that reactive oxygen species
(ROS) are involved in OA pain.
In the ACLT-induced knee OA model, nitrite levels in joint exu-
dates and iNOS in synovia were signiﬁcantly increased. Systemic
pretreatment with the non-selective iNOS inhibitor L-N(G)-nitro-
arginine methyl ester or the selective iNOS inhibitor 1,400W
reduced joint pain63, showing that NO release is associated with
such pain. Zoledronate inhibition of osteoclasts prevented cartilage
loss and pain in MIA and MMTmodels64, which suggests osteoclast
involvement in OA pain.
In the Dunkin-Hartley guinea pig model of spontaneous OA,
long-term (1 month) administration of AZ12606133, a selective
cathepsin K inhibitor, signiﬁcantly reduced mechanosensitivity in
response to both noxious and non-noxious joint movement65.
Additionally, PGEs are involved in OA pain (for a review, see
D’Souza et al., 2011). Nerve growth factor, sodium channels,
angiogenesis inhibitors, and hyaluronic acid are also involved in OA
pain66. One study of Affymetrix Gene Chip expression arrays and
articular chondrocytes from an ACLT rat model showed 1,619
differentially expressed genes67, which suggests that more bioac-
tive agents are involved in OA pain. The aforementioned bioactive
chemicals might work in concert to produce OA pain.
Spinal mechanisms
The report of variable links between injury, pain, and spreading
pain in OA patients indicates that spinal and supraspinal processing
of painful inputs are altered during OA.
Glia cells/cytokines
In the MIA-induced OA model, microglia show signiﬁcant hy-
peractivity between days 7e28, while reactive astrocytosis were
seen at day 28, the late stage of OA. Nimesulide, a COX inhibitor, and
minocycline attenuated pain behavior assessed with weight
bearing, mechanical hind paw allodynia, and microglia and astro-
cyte activation in the ipsilateral spinal cord68. MIA-injected rats
displayed reduced hind limb grip force 1, 2, and 3 weeks post-MIA,
gradual increase of phospho-extracellular signal-regulated kinase
1/2 (ERK1/2) in neurons with a signiﬁcant increase 3 weeks post-
MIA, and rapid increase of phosphorylation of p38 mitogen-
activated protein kinases in microglia and neurons that peaked a
week post-MIA. Intrathecal injection of the mitogen-activated
protein kinase 1 inhibitor PD98059 blocked hind-limb grip force
reduction and pERK1/2 induction in MIA-OA rats69. These studies
demonstrate that spinal glia are involved in OA-induced pain.
MIA injection at 5weeks resulted in signiﬁcant protein increases
in the lumbar spinal dorsal horn of multiple pro-inﬂammatory
cytokines and chemokines such as IL-1a/b, chemokine (CeC
motif) ligand 5, cytokine-induced neutrophil chemoattractant 2a/b
(CINC 2a/b), IL-13, IL-17, thymus chemokines (TC), TNF-a, L-selectin,
tissue inhibitor of metalloproteinases-1 (TIMP-1), and vascular
endothelial growth factor (VEGF). It decreased the protein levels of
IL-4 and IL-10, fractalkine, an acute spinal injury pain-associated
chemokine, and granulocyteemacrophage colony-stimulating fac-
tor in the spinal dorsal horn. Consistent with the protein data, TNF-amRNAwas increased in the spinal dorsal horn at week 5 but not at
week 2. In DRG, TNF-a and IL-1a/b mRNA increased in MIA, ACLT,
and DMM models70.
MicroRNAs-146a (miR-146a) mRNA from the lumbar DRG and
the spinal dorsal horn of MIA-injected rats signiﬁcantly decreased 2
and 4 weeks post-MIA compared to sham controls, and human
astrocytes transfected with miR-146a signiﬁcantly decreased
mRNA expression of TNF-a, COX-2, iNOS, IL-6, IL8, and TRPV171.
Most of these bioactive chemicals are involved in pain, so a miR-
146a decrease during OA might facilitate pain.
A recent study in mice demonstrated that monocyte chemo-
attractant protein (MCP)-1 (CCL2) and its high-afﬁnity receptor,
chemokine (CeCmotif) receptor 2 (CCR2), signiﬁcantly increased in
L3-5 DRG neurons at 8 weeks and returned to base levels at 16
weeks post-DMM surgery. Movement-provoked pain behaviors
appeared at 8 weeks and were maintained for at least 16 weeks. A
systemic CCR2 receptor antagonist administered to wild type DMM
mice 9 weeks after surgery reversed movement-evoked pain. After
DMM, CCR2-null mice showed an absence of movement-evoked
pain behaviors, and rapid recovery from mechanical allodynia
occurred at 4 weeks in both wild and CCR2-null mice. CCR2-null
mice also had less DRG inﬁltration by macrophages that express
numerous algogenic molecules that contribute to pain. These data
indicate that DRG neuronal MCP-1 and its receptor, CCR2, partici-
pate in the development of movement-evoked pain and the
maintenance of mechanical allodynia72.
Cannabinoids
Endocannabinoids show adaptive changes in the spinal cord
during the development of MIA-induced OA. MIA injection into the
knee not only decreased weight-bearing force and induced me-
chanical allodynia in the ipsilateral hind paw but also signiﬁcantly
facilitated spinal wide dynamic range (WDR) neuron response to
innocuous and noxious mechanical stimulation. The relationship
between weight-bearing force and WDR neuron response to hind
paw stimulation were signiﬁcantly correlated on day 28 after the
MIA injection. Further, anandamide and 2-arachidonoyl glycerol (2-
AG) as well as N-acyl phosphatidylethanolamine-speciﬁc phos-
pholipase D (NAPE-PLD) and diacylglycerol lipase alpha (DAGLa),
which synthesize anandamide and 2-AG, respectively, increased in
spinal cords of MIA-treated rats. Spinal administration of CB1
(<10 mg/50 ml) and CB2 (0.001e0.1 mg/50 ml) receptor antagonists
signiﬁcantly facilitated innocuous and noxiousmechanically evoked
responses of WDR neurons in MIA-treated but not saline-injected
rats. Administration of the endocannabinoid hydrolysis inhibitor
URB597 signiﬁcantly inhibited mechanically evoked WDR neuron
response in MIA-treated rats compared to saline-treated rats73.
These data demonstrate that spinal endocannabinoids adaptively
dampen nociceptive transmission through CB1 and CB2 receptors.
TRPV1
An early investigation showed that the protein levels of CGRP and
TRPV1 was higher in primary neurons innervating the knee in MIA-
induced OA rat model than in those of control animals74. In more
recent studies, spinal TRPV1 activities were enhanced75, and a TRPV1
antagonist alleviated hind limb grip force impairment in an MIA OA
model75,76. ATRPV1antagonist inhibitedOA-enhancedglutamate and
CGRP release in the spinal cord75 and spinal WDR and nociceptive
speciﬁc (NS) neuron response to 300-g von Frey stimulation of the
MIA-OA knee joint76. Moreover, mechanical allodyniawas relieved in
MIA-induced OA rat pretreated with the TRPV1 agonist capsaicin77,
likely due to dysfunction of nociceptive ﬁbers, and a systemic TRPV1
antagonist effectively blocked thermal hypersensitivity in MIA-
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involved in OA-related ambulatory, mechanical, and thermal pain.
Although systemic administration of the TRPV1 receptor
antagonist A-889425 reduced enhanced spontaneous ﬁring ofWDR
neurons in OA rats76, the systemic TRPV1 antagonist AMG9810 did
not block ongoing pain assessed with conditioned place preference
23. Inconsistency between the electrophysiological and behavioral
studies might be the result of the difference in MIA dosage (3 vs
4.8 mg). The assessed ongoing pain behavior involves supraspinal
mechanisms. It is possible that the TRPV1 antagonist does not
modulate activity of supraspinal neurons such as those of nucleus
accumbens which is associated with OA-induced spontaneous
pain78. Furthermore, a TRPA1 antagonist did not reduce the spon-
taneous activity of spinal WDR neurons in OA rats79, nor did a
systemic or intra-articular TRPA1 antagonist block weight asym-
metry and ongoing pain. These data suggest that MIA-induced
ongoing pain is independent of TRPV1 and TRPA1 activation23.
Additionally, since surgery-induced OA and spontaneously-
developed OA models also mimic some characteristics of human
OA, the involvement of TRPV1 in those models-induced pain war-
rant further investigation.
Neuropeptides
Intra-articular MIA induced signiﬁcant mRNA expression of SP
and CGRP in DRG neurons, and signiﬁcant increase of SP and CGRP-
immunoreactivity in synovia, periosteum, and subchondral bone on
day 21 post-MIA compared to control55. Notably, the hip joint
capsule and soft tissue in patients with painful OA also show SP and
CGRP upregulation80. Another study showed CGRP and SP upregu-
lation starting on days 7 and 28, respectively, and dynorphin (1e32)
downregulation on day 14 in the spinal cord19,81. At day 35 post-
MIA, DRG CGRP and SP declined while galanin, neuropeptide Y
and downstream regulatory element antagonist modulator
increased70. Double labeling showed that intra-articular MIA
induced CGRP upregulation in DRG neurons that innervate the knee
on day 3182. These studies indicate that OA pain can be modulated
by spinal neuropeptides. Celecoxib improved gait parameters such
as swing speed and swing phase duration, relieved mechanical
allodynia, and decreased spinal CGRP but not SP in MIA-induced OA
rat model19. Eugenol, the main constituent of clove oil, improved
dynamic gait parameters (swing speed, swing phase duration and
duty cycle) and mechanical allodynia of the affected limb.
Concomitantly, it decreased spinal SP and CGRP and increased spinal
dynorphin inMIA-induced OA rat model83. Furthermore, intrathecal
injection of the peptide antagonist CGRP (8e37) mitigated MIA-
induced mechanical allodynia84. These studies suggest that chem-
icals that reverse spinal neuropeptide regulation alleviate OA pain.
Neuropathic components of OA pain
Because of alterations in the central nervous system and the
peripheral nerves that innervate the joints, OA-associated pain
gradually develops the characteristics of neuropathic pain85. Pre-
vious studies show that activation of a marker of nerve injury,
transcript factor (ATF-3) in the DRG, signiﬁcantly increased be-
tween days 8 and 14 post-MIA and that NSAID analgesia peaked on
day 14 and decreased in efﬁcacy thereafter85. This indicates a
transition at days 8e14 from early inﬂammatory pain to late-stage
inﬂammatory-neuropathic pain. Another study also showed that
ATF3-immunoreactive growth-associated protein-43-immunoreactive
DRG neurons signiﬁcantly increased in the ipsilateral DRG 14
days after the injection29. Additionally, an MIA injection resulted
in a signiﬁcant reduction in intra-epidermal nerve ﬁber density
of the plantar hind paw post-MIA between days 7 and 1486.Microgliosis, a characteristic of neuropathic pain87, also occurs in
the spinal cord 7e21 days post-MIA29,86. Taken together, these
data suggest that neuronal damage occurs during the development
ofOA,whichmight explainwhyOApain treatment andmanagement
is unsuccessful. It is not known whether surgery-induced and
spontaneously-developed OA models show any characteristics of
nerve injury, which warrant further investigation.
Supraspinal mechanisms
A study showed that electroacupuncture (EA) signiﬁcantly
improved MIA-induced hind limb incapacity within 7 days of the
MIA injection; the effect was prevented by 5-hydroxytryptamine
(5-HT) 2A/C antagonism. This suggests that EA activates descend-
ing inhibitory 5-HT to inhibit early-stage OA-pain88.
Studies in rats demonstrate that, compared to a saline injection,
spinal WDR neurons show stimulus intensity-dependent and
signiﬁcantly enhanced response to mechanical stimulation 15e19
days after an intra-articular MIA injection. Response to thermal
stimulation was also higher in MIA- than in saline-injected rats,
although this response was not statistically signiﬁcant. Further,
spinal 5-HT3 antagonism signiﬁcantly decreased the neuron
response induced by tactile mechanical stimulus and produced
greater inhibition of response to 45C thermal stimulation in MIA
rats than in control. These data indicate tactile mechanical and
noxious thermal stimulation-evoked responses are facilitated by
spinal 5-HT3 receptors. Since spinal 5-HT is supraspinally pro-
duced, descending 5-HT/5-HT3 receptor facilitation might
contribute to OA-induced pain. Moreover, the a2d-1 subunit of
voltage-gated calcium channels (VGCCs) increased in ipsilateral
DRG in MIA rats compared to control. Consistent with these results,
pregabalin inhibited spinal neuronal responses evoked by noxious
electrical stimulation and innocuous and noxious natural stimula-
tion in MIA but not in saline control rats. This inhibition was pre-
vented by 5-HT3 receptor antagonism. Therefore, descending 5-HT/
5-HT3 facilitation coupled with upregulation of a2d-1 VGCC sub-
unit expression might contribute to OA pain89.
Recently, a study in the MIA model demonstrated that intra-
articular lidocaine induces conditioned place preference for the
lidocaine-paired compartment, indicating OA pain has an aversive
component23. This suggests that OA pain also involves supraspinal
mechanisms. Although clinical imaging studies demonstrate brain
changes during chronic pain, image studies have not beenperformed
in OA pain animal models until recently. In an MMT animal model,
increased functional connectivity was observed 3e5 weeks post
MMT in nucleus accumbens- and ventral posterior lateral thalamus-
based functional connectivity analyses. Those changes were atten-
uated by sustained treatment with a broad-spectrumMMP inhibitor
or acute treatment with celecoxib90. In humans, gray matter de-
creases in the anterior cingulate cortex (ACC), dorsolateral prefrontal
cortex, amygdala, and brainstem were reversed when patients feel
no hip OA-induced pain after hip replacement surgery. This suggests
that brain changes are related to the pain91. Additionally, it has been
reported that nucleus accumbens activity is associated with spon-
taneous OA-induced pain78 and facilitates nociception92. Whether
this increased functional connectivity during OA contributes to
chronic pain requires further investigation.
Conclusion
OA is the most common form of joint disease. Recent studies on
OA-induced pain demonstrate that peripheral pro-inﬂammatory
mediators and neuropeptides can sensitize knee nociceptors
(Fig. 1). The pro-nociceptive plasticity of spinal cytokines and
neuropeptides promotes OA-associated pain. Peripheral and spinal
R.-X. Zhang et al. / Osteoarthritis and Cartilage 21 (2013) 1308e1315 1313cannabinoids might respectively inhibit OA pain through CB1 and
CB1/CB2 receptors. TRPV1 contributes to OA pain (Fig. 1). MMP-13
inhibitor reduces MIA-induced cartilage damage and indirectly al-
leviates pain54. Other bioactive chemicals such as sphingosine
kinase-2, Rho kinase, kinin B(2) receptors, ROS, iNOS, cathepsin K,
PGEs, nerve growth factor, and sodium channels are all involved in
OA pain, and supraspinal descending facilitation of 5-HT/5-HT3
receptors might contribute to OA pain. During OA, brain functional
connectivity is enhanced, but how connectivity changes are related
to OA pain remains elusive.Author contributions
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